104 related articles for article (PubMed ID: 21963844)
1. Four proteins governing overangiogenic endothelial cell phenotype in patients with multiple myeloma are plausible therapeutic targets.
Berardi S; Caivano A; Ria R; Nico B; Savino R; Terracciano R; De Tullio G; Ferrucci A; De Luisi A; Moschetta M; Mangialardi G; Catacchio I; Basile A; Guarini A; Zito A; Ditonno P; Musto P; Dammacco F; Ribatti D; Vacca A
Oncogene; 2012 May; 31(18):2258-69. PubMed ID: 21963844
[TBL] [Abstract][Full Text] [Related]
2. HIF-1α of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target.
Ria R; Catacchio I; Berardi S; De Luisi A; Caivano A; Piccoli C; Ruggieri V; Frassanito MA; Ribatti D; Nico B; Annese T; Ruggieri S; Guarini A; Minoia C; Ditonno P; Angelucci E; Derudas D; Moschetta M; Dammacco F; Vacca A
Clin Cancer Res; 2014 Feb; 20(4):847-58. PubMed ID: 24297864
[TBL] [Abstract][Full Text] [Related]
3. A HGF/cMET autocrine loop is operative in multiple myeloma bone marrow endothelial cells and may represent a novel therapeutic target.
Ferrucci A; Moschetta M; Frassanito MA; Berardi S; Catacchio I; Ria R; Racanelli V; Caivano A; Solimando AG; Vergara D; Maffia M; Latorre D; Rizzello A; Zito A; Ditonno P; Maiorano E; Ribatti D; Vacca A
Clin Cancer Res; 2014 Nov; 20(22):5796-807. PubMed ID: 25212607
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma.
De Luisi A; Ferrucci A; Coluccia AM; Ria R; Moschetta M; de Luca E; Pieroni L; Maffia M; Urbani A; Di Pietro G; Guarini A; Ranieri G; Ditonno P; Berardi S; Caivano A; Basile A; Cascavilla N; Capalbo S; Quarta G; Dammacco F; Ribatti D; Vacca A
Clin Cancer Res; 2011 Apr; 17(7):1935-46. PubMed ID: 21307145
[TBL] [Abstract][Full Text] [Related]
5. Role of erythropoietin in the angiogenic activity of bone marrow endothelial cells of MGUS and multiple myeloma patients.
Lamanuzzi A; Saltarella I; Ferrucci A; Ria R; Ruggieri S; Racanelli V; Rao L; Annese T; Nico B; Vacca A; Ribatti D
Oncotarget; 2016 Mar; 7(12):14510-21. PubMed ID: 26919105
[TBL] [Abstract][Full Text] [Related]
6. Role of Endothelial Cells and Fibroblasts in Multiple Myeloma Angiogenic Switch.
Ribatti D; Vacca A
Cancer Treat Res; 2016; 169():51-61. PubMed ID: 27696258
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.
Roccaro AM; Hideshima T; Raje N; Kumar S; Ishitsuka K; Yasui H; Shiraishi N; Ribatti D; Nico B; Vacca A; Dammacco F; Richardson PG; Anderson KC
Cancer Res; 2006 Jan; 66(1):184-91. PubMed ID: 16397231
[TBL] [Abstract][Full Text] [Related]
8. Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma.
Vacca A; Scavelli C; Montefusco V; Di Pietro G; Neri A; Mattioli M; Bicciato S; Nico B; Ribatti D; Dammacco F; Corradini P
J Clin Oncol; 2005 Aug; 23(23):5334-46. PubMed ID: 15939924
[TBL] [Abstract][Full Text] [Related]
9. Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients.
Basile A; Moschetta M; Ditonno P; Ria R; Marech I; De Luisi A; Berardi S; Frassanito MA; Angelucci E; Derudas D; Specchia G; Curci P; Pavone V; Rossini B; Ribatti D; Bottazzi B; Mantovani A; Presta M; Dammacco F; Vacca A
J Pathol; 2013 Jan; 229(1):87-98. PubMed ID: 22847671
[TBL] [Abstract][Full Text] [Related]
10. Homotypic and Heterotypic Activation of the Notch Pathway in Multiple Myeloma-Enhanced Angiogenesis: A Novel Therapeutic Target?
Saltarella I; Frassanito MA; Lamanuzzi A; Brevi A; Leone P; Desantis V; Di Marzo L; Bellone M; Derudas D; Ribatti D; Chiaramonte R; Palano MT; Neri A; Mariggiò MA; Fumarulo R; Dammacco F; Racanelli V; Vacca A; Ria R
Neoplasia; 2019 Jan; 21(1):93-105. PubMed ID: 30529074
[TBL] [Abstract][Full Text] [Related]
11. Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma.
Scavelli C; Nico B; Cirulli T; Ria R; Di Pietro G; Mangieri D; Bacigalupo A; Mangialardi G; Coluccia AM; Caravita T; Molica S; Ribatti D; Dammacco F; Vacca A
Oncogene; 2008 Jan; 27(5):663-74. PubMed ID: 17667938
[TBL] [Abstract][Full Text] [Related]
12. Thrombopoietin Promotes Angiogenesis and Disease Progression in Patients with Multiple Myeloma.
Lamanuzzi A; Saltarella I; Frassanito MA; Ribatti D; Melaccio A; Desantis V; Solimando AG; Ria R; Vacca A
Am J Pathol; 2021 Apr; 191(4):748-758. PubMed ID: 33516787
[TBL] [Abstract][Full Text] [Related]
13. Endothelial differentiation of hematopoietic stem and progenitor cells from patients with multiple myeloma.
Ria R; Piccoli C; Cirulli T; Falzetti F; Mangialardi G; Guidolin D; Tabilio A; Di Renzo N; Guarini A; Ribatti D; Dammacco F; Vacca A
Clin Cancer Res; 2008 Mar; 14(6):1678-85. PubMed ID: 18347168
[TBL] [Abstract][Full Text] [Related]
14. A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma.
Vacca A; Ria R; Ribatti D; Semeraro F; Djonov V; Di Raimondo F; Dammacco F
Haematologica; 2003 Feb; 88(2):176-85. PubMed ID: 12604407
[TBL] [Abstract][Full Text] [Related]
15. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
Di Raimondo F; Azzaro MP; Palumbo G; Bagnato S; Giustolisi G; Floridia P; Sortino G; Giustolisi R
Haematologica; 2000 Aug; 85(8):800-5. PubMed ID: 10942925
[TBL] [Abstract][Full Text] [Related]
16. Loss of inhibitory semaphorin 3A (SEMA3A) autocrine loops in bone marrow endothelial cells of patients with multiple myeloma.
Vacca A; Scavelli C; Serini G; Di Pietro G; Cirulli T; Merchionne F; Ribatti D; Bussolino F; Guidolin D; Piaggio G; Bacigalupo A; Dammacco F
Blood; 2006 Sep; 108(5):1661-7. PubMed ID: 16684957
[TBL] [Abstract][Full Text] [Related]
17. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment.
Du W; Hattori Y; Hashiguchi A; Kondoh K; Hozumi N; Ikeda Y; Sakamoto M; Hata J; Yamada T
Pathol Int; 2004 May; 54(5):285-94. PubMed ID: 15086832
[TBL] [Abstract][Full Text] [Related]
18. Gene expression profiling of bone marrow endothelial cells in patients with multiple myeloma.
Ria R; Todoerti K; Berardi S; Coluccia AM; De Luisi A; Mattioli M; Ronchetti D; Morabito F; Guarini A; Petrucci MT; Dammacco F; Ribatti D; Neri A; Vacca A
Clin Cancer Res; 2009 Sep; 15(17):5369-78. PubMed ID: 19690192
[TBL] [Abstract][Full Text] [Related]
19. [Link between osteoclastogenesis, angiogenesis and myeloma expansion].
Abe M
Clin Calcium; 2008 Apr; 18(4):473-9. PubMed ID: 18379029
[TBL] [Abstract][Full Text] [Related]
20. Epha3 acts as proangiogenic factor in multiple myeloma.
Caivano A; La Rocca F; Laurenzana I; Annese T; Tamma R; Famigliari U; Simeon V; Trino S; De Luca L; Villani O; Berardi S; Basile A; Vacca A; Saglio G; Del Vecchio L; Musto P; Cilloni D
Oncotarget; 2017 May; 8(21):34298-34309. PubMed ID: 28415715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]